A Phase 2 interventional study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, sponsored by AstraZeneca. Completed at 17 sites in 7 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).
The study protocol follows a modular design. The study will investigate the safety and efficacy of capivasertib monotherapy in participants with R/R Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL).
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Module 1 specific inclusion criteria:
Additional Inclusion Criteria for Cohort 1A (R/R FL):
Additional Inclusion Criteria for Cohort 1B (R/R MZL):
Additional Inclusion Criteria for Cohort 1C (R/R MCL):
Participants must have received as prior therapies
Prior regimens must have included:
Exclusion Criteria:
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values at screening:
Prior treatment with any of the following:
Additional exclusion core criteria may apply, please refer to the protocol
Module 1 specific exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.
Drug: Capivasertib
Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.
Objective Response Rate
Objective response rate is defined as the proportion of patients achieving either complete response (CR) or partial response (PR) according to the Lugano 2014 Classification for non-Hodgkin lymphoma (NHL) as assessed by blinded independent central review (BICR).
Time frame: First dose until progression of disease [PD] or last evaluable assessment in the absence of progression or data cut-off date (21.6 Months)
Duration of Response
Duration of response is defined as the time from the date of first documented response until date of documented progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause.
Time frame: First documented response until date of documented progression or data-cut off date (21.6 Months)
Progression-free Survival
Progression-free survival is defined as the time from the date of first dose until documented disease progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause. The analysis included all dosed patients, regardless of whether the patient withdrew from therapy, received another anti lymphoma therapy, or clinically progressed prior to progression according to the Lugano 2014 Classification for NHL.
Time frame: First dose until documented disease progression or data cut-off date (21.6 Months)
Overall Survival (OS)
Overall survival is defined as time from the date of first dose until the date of death due to any cause. The analysis included all dosed patients, regardless of whether the patient withdrew from therapy or received another anti lymphoma therapy. Patients who had not died by the analysis DCO date were censored at their last known date of being alive before the DCO date. Patients who were known to be alive or dead after the DCO date were censored at the DCO date. Patients who were lost to follow-up were censored at the date when they were last known to have been alive.
Time frame: First dose until data cut-off date (21.6 Months)
Number of Patients With Adverse Events and Serious Adverse Events
The safety and tolerability of the capivasertib treatment in each Cohort was assessed.
Time frame: Screening (Day -28 to -1) until Post-treatment follow-up up to 30 days after last dose or long-term follow-up or study completion (Every 12 weeks until death or lost to follow-up, unless patient have withdrawn consent [up to 21.6 Months])
Plasma Concentration of Capivasertib Overtime
The plasma concentration of capivasertib when administered in patients in each Cohort was determined.
Time frame: Cycle 1 (28-day treatment Cycle) Day 1 and on Cycle 1 Day 8, Cycle 1 Day 15 and Cycle 1 Day 22 (Pre-dose and post-dose)
The study was conducted from 3 November 2021 and analyses presented in this results form are based on a data cut-off of 22 August 2023.
| Milestone | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy |
|---|---|---|---|
| Started | 16 | 4 | 10 |
| Completed | 13 | 3 | 9 |
| Not completed | 3 | 1 | 1 |
| Withdrew: Patients ongoing treatment at data cut-off date of 22 august 2023. | 3 | 1 | 1 |
Objective response rate is defined as the proportion of patients achieving either complete response (CR) or partial response (PR) according to the Lugano 2014 Classification for non-Hodgkin lymphoma (NHL) as assessed by blinded independent central review (BICR).
| Percentage of Patients | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy |
|---|---|---|---|
| Objective Response Rate | 18.8 (4.0 to 45.6) | 33.3 (0.8 to 90.6) | 30.0 (6.7 to 65.2) |
Duration of response is defined as the time from the date of first documented response until date of documented progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause.
| Months | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy |
|---|---|---|---|
| Duration of Response | 1.9 (1.7 to NA) | NA (NA to NA) | 1.9 (NA to NA) |
Progression-free survival is defined as the time from the date of first dose until documented disease progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause. The analysis included all dosed patients, regardless of whether the patient withdrew from therapy, received another anti lymphoma therapy, or clinically progressed prior to progression according to the Lugano 2014 Classification for NHL.
| Months | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy |
|---|---|---|---|
| Progression-free Survival | 5.4 (3.4 to NA) | NA (1.4 to NA) | 1.9 (0.9 to NA) |
Overall survival is defined as time from the date of first dose until the date of death due to any cause. The analysis included all dosed patients, regardless of whether the patient withdrew from therapy or received another anti lymphoma therapy. Patients who had not died by the analysis DCO date were censored at their last known date of being alive before the DCO date. Patients who were known to be alive or dead after the DCO date were censored at the DCO date. Patients who were lost to follow-up were censored at the date when they were last known to have been alive.
| Months | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy |
|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (1.4 to NA) | NA (2.0 to NA) |
The safety and tolerability of the capivasertib treatment in each Cohort was assessed.
| Participants | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy |
|---|---|---|---|
| Any adverse event (AE) | 16 | 3 | 10 |
| Any AE possibly related to treatment | 14 | 3 | 8 |
| Any AE of CTCAE grade 3 or higher | 7 | 1 | 7 |
| Any AE of CTCAE grade 3 or higher, possibly related to treatment | 3 | 1 | 5 |
| Any AE with outcome = death | 0 | 0 | 0 |
| Any AE with outcome = death, possibly related to treatment | 0 | 0 | 0 |
| Any SAE (including events with outcome = death) | 2 | 0 | 3 |
| Any SAE (including events with outcome = death), possibly related to treatment | 0 | 0 | 3 |
The plasma concentration of capivasertib when administered in patients in each Cohort was determined.
| ng/mL | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy |
|---|---|---|---|
| Cycle 1 Day 1 (Post-dose [1 hour]) | 394.9 ± 157.0 | 414.4 ± 125.7 | 287.1 ± 676.2 |
| Cycle 1 Day 1 (Post-dose [2 hours]) | 883.7 ± 59.12 | 962.9 ± 40.33 | 976.1 ± 58.27 |
| Cycle 1 Day 1 (Post-dose [4 hours]) | 528.5 ± 49.28 | 677.2 ± 65.77 | 780.1 ± 56.99 |
| Cycle 1 Day 8 (Pre-dose) | 6.149 ± 207.4 | 8.477 ± 103.9 | 14.31 ± 138.8 |
| Cycle 1 Day 15 (Pre-dose) | 5.844 ± 146.1 | 9.245 ± 73.63 | 32.36 ± 373.5 |
| Cycle 1 Day 22 (Pre-dose) | 7.974 ± 372.2 | NA ± NA | NA ± NA |
Collected over Screening (Day -28 to -1) until Post-treatment follow-up up to 30 days after last dose or long-term follow-up or study completion (Every 12 weeks until death or lost to follow-up, unless patient have withdrawn consent [up to 21.6 Months]). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | 0/16 (0%) | 2/16 (12.5%) | 16/16 (100%) |
| Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | 1/4 (25%) | 0/4 (0%) | 3/4 (75%) |
| Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy | 2/10 (20%) | 3/10 (30%) | 9/10 (90%) |
| Event | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy |
|---|---|---|---|
| Perirectal abscessInfections and infestations | 0/16 | 0/4 | 1/10 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/16 | 0/4 | 1/10 |
| DiarrhoeaGastrointestinal disorders | 0/16 | 0/4 | 1/10 |
| Erythema multiformeSkin and subcutaneous tissue disorders | 0/16 | 0/4 | 1/10 |
| COVID-19 pneumoniaInfections and infestations | 1/16 | 0/4 | 0/10 |
| Obliterative bronchiolitisRespiratory, thoracic and mediastinal disorders | 1/16 | 0/4 | 0/10 |
| Event | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 15/16 | 2/4 | 4/10 |
| NauseaGastrointestinal disorders | 2/16 | 2/4 | 5/10 |
| RashSkin and subcutaneous tissue disorders | 2/16 | 0/4 | 3/10 |
| COVID-19Infections and infestations | 0/16 | 1/4 | 1/10 |
| Respiratory tract infectionInfections and infestations | 0/16 | 1/4 | 0/10 |
| AnaemiaBlood and lymphatic system disorders | 1/16 | 1/4 | 0/10 |
| Decreased appetiteMetabolism and nutrition disorders | 2/16 | 1/4 | 1/10 |
| HyperuricaemiaMetabolism and nutrition disorders | 0/16 | 1/4 | 2/10 |
| HeadacheNervous system disorders | 3/16 | 1/4 | 0/10 |
| Deep vein thrombosisVascular disorders | 0/16 | 1/4 | 0/10 |
Safety analysis set included for baseline characteristics, and it included all patients who received any amount of study treatment.
| Age, Continuous(Years) | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy | Total |
|---|---|---|---|---|
| Mean | 55.7 ± 12.07 | 66.8 ± 4.92 | 76.2 ± 9.72 | 64.0 ± 14.06 |
| Sex: Female, Male(Participants) | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy | Total |
|---|---|---|---|---|
| Female | 7 | 2 | 4 | 13 |
| Male | 9 | 2 | 6 | 17 |
| Race/Ethnicity, Customized(Participants) | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy | Total |
|---|---|---|---|---|
| Asian | 5 | 0 | 0 | 5 |
| White | 10 | 3 | 7 | 20 |
| Other | 0 | 1 | 1 | 2 |
| Not reported | 1 | 0 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy | Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy | Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 0 | 3 |
| Not Hispanic or Latino | 12 | 4 | 5 | 21 |
| Missing | 0 | 0 | 4 | 4 |
| Other | 1 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patientlevel data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2021 to primary completion in Aug 2023, 21 months.
Results were first posted in Jun 2024, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capivasertib